Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ulhas Nadgir

Pediatric Endocrinology Sacramento, CA Medical Doctor

NPI 1629079215 CMS profile 119558

3814 Auburn Blvd, Suite 72, Sacramento, CA 95821

Open in the dashboard

General payments

$13,672

671 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$707,710 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Ulhas Nadgir of Sacramento, CA is reported in the CMS Open Payments database as having received $13,672 across 671 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $707,710 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,753 76
2024 General $938 46
2023 General $2,448 141
2022 General $2,689 153
2021 General $1,865 118
2020 General $957 64
2019 General $1,020 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ulhas Nadgir
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Ulhas Nadgir were reported at $3,753. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Ulhas Nadgir Pediatric Endocrinology median Middle half National median
2019 $1,020 $196 $68–$845 $163
2020 $957 $124 $37–$722 $114
2021 $1,865 $134 $35–$691 $132
2022 $2,689 $177 $47–$726 $149
2023 $2,448 $236 $75–$887 $160
2024 $938 $259 $91–$979 $164
2025 $3,753 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,124 178 payments
  2. Janssen Research & Development, LLC $1,875 1 payment
  3. Novo Nordisk Inc $1,069 94 payments
  4. Tandem Diabetes Care, Inc. $1,050 40 payments
  5. Abbott Laboratories $828 38 payments
  6. Mannkind Corporation $752 39 payments
  7. Alexion Pharmaceuticals, Inc. $633 22 payments
  8. Lilly USA, LLC $611 39 payments
  9. Insulet Corporation $505 26 payments
  10. Ascendis Pharma, Inc. $494 15 payments
  11. Other $3,730 179 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,693 666 payments
  2. Consulting Fee $1,875 1 payment
  3. Gift $59 1 payment
  4. Long term medical supply or device loan $40 1 payment
  5. Education $4 2 payments
Products named General payments · program years 2019–2025
  1. INVOKANA $1,875 1 payment
  2. LUPRON DEPOT $1,779 153 payments
  3. t:slim X2 Insulin Pump with Control-IQ $793 21 payments
  4. AFREZZA $752 39 payments
  5. BAQSIMI $552 32 payments
  6. STRENSIQ $489 16 payments
  7. SKYTROFA $471 14 payments
  8. Omnipod $447 23 payments
  9. FreeStyle Libre 3 $427 19 payments
  10. Norditropin $354 21 payments
  11. Other $6,893 354 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

671 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record